Cancer

Department of Health written question – answered on 12th July 2016.

Alert me about debates like this

Photo of David Tredinnick David Tredinnick Conservative, Bosworth

To ask the Secretary of State for Health, if he will take steps to review the decision to remove peptide receptor radionuclide therapy treatments from the Cancer Drugs Fund list.

Photo of George Freeman George Freeman The Parliamentary Under-Secretary of State for Business, Innovation and Skills, The Parliamentary Under-Secretary of State for Health

The National Institute for Health and Care Excellence (NICE) is currently appraising the peptide receptor radionuclide therapy treatment lutetium-177-DOTA octreotate for the treatment of neuroendocrine tumours and for gastroenteropancreatic neuroendocrine tumours.

NHS England has advised that it will await the outcome of NICE’s appraisals before making any commissioning decisions on peptide receptor radionuclide therapy treatments.

In the meantime, if a patient’s condition is considered clinically exceptional, then an application can be considered under NHS England’s Individual Funding Request system.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.